Ferraz, Spain

Fernando Cillero Grafulla

This inventor holds 1 USPTO granted patent. Top assignee: Alter, S.a.. Active years: 1977.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 1977

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Fernando Cillero Grafulla

Introduction

Fernando Cillero Grafulla is an accomplished inventor based in Ferraz, Spain. He has made significant contributions to the field of chemical engineering, particularly in the preparation of glycol compounds. His innovative approach has led to the development of a unique process that enhances the efficiency of glycol production.

Latest Patents

Cillero Grafulla holds a patent for the "Preparation of glycol 2-(p-chlorophenoxy)-2-methylpropionate nicotinate." This invention provides a process characterized by the reaction of 2-(p-chlorophenoxy)-2-methylpropionic acid with ethylene oxide in an inert solvent, utilizing a catalyst. The process results in the formation of a monoglycol ester, which is subsequently reacted with nicotinic acid chloride to yield the final product.

Career Highlights

Throughout his career, Fernando has demonstrated a commitment to innovation and excellence in his field. He is currently associated with Alter, S.A., where he continues to develop and refine his inventions. His work has not only contributed to the advancement of chemical processes but has also positioned him as a notable figure in the industry.

Collaborations

Fernando collaborates with Carlos Sunkel Letelier, enhancing the scope and impact of their research and development efforts. Their partnership exemplifies the importance of teamwork in driving innovation.

Conclusion

Fernando Cillero Grafulla's contributions to the field of chemical engineering through his innovative patent demonstrate his expertise and commitment to advancing technology. His work continues to influence the industry and inspire future innovations.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…